Company news: IMS, SDI and inVentiv Health

Share this article:
IMS said global spending on medicine will slow over the next five years to 3%-6% reflecting slowing growth in developed markets due to patent losses and policy changes – compared to a CAGR of 6.2% for the past five years. The data firm cited lower spending growth in the US, the continuing impact of patent expiries and belt-tightening as factors in the slowdown, offset by continued strong growth in emerging markets like Brazil, Russia, India and China, whose collective spending will become the second largest behind the US, surpassing Europe as a profit center for pharmas. 
 
SDI's Pollen.com launched an allergy alert app for Ford's dashboard SYNC system, aimed at reducing driver distractions. The app offers one-day alerts and four-day location-specific forecasts on allergy, asthma, cold and cough, along with UV sensitivity. 
 
InVentiv Health is buying contract research organization PharmaNet Development Group. It's the firm's second CRO investment since January.
Share this article:

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.